Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon-alpha Omniferon - Viragen

Drug Profile

Interferon-alpha Omniferon - Viragen

Alternative Names: alpha-IF; Natural human interferon-alpha; Natural human leukocyte interferon-alpha; Omniferon

Latest Information Update: 04 Feb 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viragen; ViraNative
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haematological malignancies; Hepatitis C; Herpes simplex virus infections; HIV infections; Leukaemia; Multiple sclerosis

Most Recent Events

  • 28 Sep 2001 Suspended-II for Hepatitis C in Europe (SC)
  • 29 Jun 2001 Viragen has received UK approval to begin clinical trials with OmniferonTM for the treatment of multiple sclerosis
  • 09 Feb 2001 Pall Corporation will supply leukocytes fo Viragen for manufacture of OmniferonTM
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top